Primary Hyperoxaluria Type 1 Therapeutics
1. Oxlumo patent expiration
Treatment: Treatment of primary hyperoxaluria type 1 (ph1)
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11401517 | ALNYLAM | Modified double-stranded RNA agents |
Aug, 2035
(9 years from now) | |
| US11060093 | ALNYLAM | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA |
Dec, 2034
(8 years from now) | |
| US10487330 | ALNYLAM | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA |
Dec, 2034
(8 years from now) | |
| US11261447 | ALNYLAM | Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression |
Nov, 2038
(12 years from now) | |
| US9828606 | ALNYLAM | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA |
Dec, 2034
(8 years from now) | |
| US10478500 | ALNYLAM | Compositions and methods for inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) gene expression |
Oct, 2035
(9 years from now) | |
| US8106022 | ALNYLAM | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2029
(3 years from now) | |
| US8828956 | ALNYLAM | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(2 years from now) | |
| US10131907 | ALNYLAM | Glycoconjugates of RNA interference agents |
Aug, 2028
(2 years from now) | |
| US10612024 | ALNYLAM | Modified double-stranded RNA agents |
Aug, 2035
(9 years from now) | |
| US10612027 | ALNYLAM | Modified double-stranded RNA agents |
Aug, 2035
(9 years from now) | |
| US10465195 | ALNYLAM | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA |
Dec, 2034
(8 years from now) | |
| US11446380 | ALNYLAM | Compositions and methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression |
Oct, 2035
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10435692 | ALNYLAM | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA |
Dec, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-901) | Oct 06, 2025 |
| New Chemical Entity Exclusivity(NCE) | Nov 23, 2025 |
| Orphan Drug Exclusivity(ODE-339) | Nov 23, 2027 |
| Orphan Drug Exclusivity(ODE-415) | Oct 06, 2029 |
Drugs and Companies using LUMASIRAN SODIUM ingredient
NCE-1 date: 23 November, 2024
Market Authorisation Date: 23 November, 2020
Dosage: SOLUTION
More Information on Dosage
OXLUMO family patents
2. Rivfloza patent expiration
Treatment: Method of treating primary hyperoxaluria type 1 (ph1)
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11286488 | NOVO NORDISK | Methods and compositions for inhibiting expression of LDHA |
Oct, 2038
(12 years from now) | |
| US10738311 | NOVO NORDISK | Therapeutic inhibition of lactate dehydrogenase and agents therefor |
Oct, 2035
(9 years from now) | |
| US11053502 | NOVO NORDISK | Therapeutic inhibition of lactate dehydrogenase and agents therefor |
Oct, 2035
(9 years from now) | |
| US11359203 | NOVO NORDISK | Therapeutic inhibition of lactate dehydrogenase and agents therefor |
Oct, 2035
(9 years from now) | |
| US11661604 | NOVO NORDISK | Methods and compositions for inhibiting expression of LDHA |
Oct, 2038
(12 years from now) | |
| US10351854 | NOVO NORDISK | Therapeutic inhibition of lactate dehydrogenase and agents therefor |
Oct, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Mar 27, 2028 |
| New Chemical Entity Exclusivity(NCE) | Sep 29, 2028 |
| Orphan Drug Exclusivity(ODE-443) | Sep 29, 2030 |
Drugs and Companies using NEDOSIRAN SODIUM ingredient
NCE-1 date: 30 September, 2027
Market Authorisation Date: 29 September, 2023
Dosage: SOLUTION
More Information on Dosage
RIVFLOZA family patents